Form 8-K - Current report:
SEC Accession No. 0001104659-24-122587
Filing Date
2024-11-25
Accepted
2024-11-25 16:30:57
Documents
20
Period of Report
2024-11-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2428677d4_8k.htm   iXBRL 8-K 42465
2 EXHIBIT 1.1 tm2428677d4_ex1-1.htm EX-1.1 224589
3 EXHIBIT 4.1 tm2428677d4_ex4-1.htm EX-4.1 96505
4 EXHIBIT 4.2 tm2428677d4_ex4-2.htm EX-4.2 100957
5 EXHIBIT 5.1 tm2428677d4_ex5-1.htm EX-5.1 19978
9 GRAPHIC tm2428677d4_ex4-1img001.jpg GRAPHIC 1863
10 GRAPHIC tm2428677d4_ex4-2img001.jpg GRAPHIC 1731
11 GRAPHIC tm2428677d4_ex5-1img001.jpg GRAPHIC 2559
  Complete submission text file 0001104659-24-122587.txt   775791

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA btai-20241122.xsd EX-101.SCH 3048
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE btai-20241122_lab.xml EX-101.LAB 34240
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE btai-20241122_pre.xml EX-101.PRE 22381
22 EXTRACTED XBRL INSTANCE DOCUMENT tm2428677d4_8k_htm.xml XML 3562
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Filer) CIK: 0001720893 (see all company filings)

EIN.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38410 | Film No.: 241496358
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)